Bioabsorbable/Nufairy Coil Application Trial in China (NuCATCH)

A Prospective, Multi-center, Open-label, Non-inferiority, Randomized, Controlled Trial of Bioabsorbable/Nufairy Coil Embolization System for the Treatment of Intracranial Aneurysms

The scope of this trial is the collection and analysis of effectiveness and safety endpoints, related to the use of the Bioabsorbable/Nufairy Coil Embolization System in the treatment of intracranial aneurysms.

Study Overview

• Status: Active, not recruiting
• Conditions: Intracranial Aneurysm
• Intervention / Treatment: Device: Nufairy® Coil embolization system for intracranial aneurysm

Detailed Description

Approximately 258 subjects with intracranial aneurysms would be enrolled for coiling embolization according to the inclusion and exclusion criteria specified in this trial protocol. Subjects were evaluated by mRS preoperatively, at the time of device implantation, at the time of discharge from the hospital, at 1 month (±7 days) postoperatively, at 6 months (±30 days) postoperatively, and at 12 months (±90 days) postoperatively; subjects would underwent DSA imaging at surgery and at 12months (±90 days) postoperatively, and MRA imaging at 18 months (±90 days) postoperatively. Unplanned follow-up of the subjects would performed when necessary, and data would be recorded to evaluate the safety and efficacy of Nufairy Coil Embolization System for coiling embolization for the treatment of intracranial aneurysms.

• Study Type: Interventional
• Enrollment (Estimated): 258
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Shanghai, China
    • Shanghai Changhai Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Male or female ≥18 years old and ≤80 years old at the time of signing the informed consent;
2. Intracranial aneurysm diagnosed by CTA, MRA, DSA neuroimaging examination;
3. Subjects whose target aneurysms are suitable for embolization with flow diverter or intracranial arterial stents assisted by coils, and the entire treatment can be performed in a single procedure;
4. The subjects or the subject's guardian signs the informed consent voluntarily and is willing to accept follow-up.

Exclusion Criteria:

1. mRS Score ≥3 points in clinical assessment prior to enrollment;
2. Subjects who received neurosurgical or endovascular treatment for recurrent aneurysms;
3. Subjects with multiple aneurysms;
4. Subjects with ruptured aneurysms <30 days;
5. Significant stenosis (≥50%) of parent artery;
6. Subjects who are not suitable for anesthesia or intravascular surgery, such as major diseases of the heart, lung, liver, spleen, kidney, brain tumors, severe active infections, disseminated intravascular coagulation, and a history of serious mental illness;
7. Subjects who have undergone major surgical procedures (such as internal fixation device implantation of limbs fracture, tumor resection, major organ surgery, etc.) within 30 days before signing the informed consent or plan to undergo major surgical procedures within 60 days after signing the informed consent;
8. Subjects with morphology or lesions that may interfere with device use, including but not limited to: carotid artery dissection, vasculitis, aortic dissection, limited vascular access (e.g., severe intracranial vessel tortuosity, severe intracranial vessel spasm that does not respond to medical treatment, other anatomical or clinical changes that impede device access;
9. Treatment contrainidations of coils, including but not limited to: contrainidations of digital subtraction angiography, allergy to or intolerance of contrast agents, allergy to or intolerance of anti-platelet and anticoagulant drugs required for treatment, platinum-tungsten alloy, and poly(co-glycolic acid) (PLGA);
10. Pregnant or lactating women;
11. Life expectancy is less than 18 months;
12. Subjects participating in other drug or device studies did not meet the endpoint.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental group; Bioabsorbable/Nufairy coil embolization system	Device: Nufairy® Coil embolization system for intracranial aneurysm; Nufairy® Coil embolization system for intracranial aneurysm
Active Comparator: Control group; Numen coil embolization system	Device: Nufairy® Coil embolization system for intracranial aneurysm; Nufairy® Coil embolization system for intracranial aneurysm

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Successful occlusion rate of aneurysm at 12-month post-procedure.	It was defined as the percentage of subjects with the degree of aneurysm embolization scored as Raymond I or II (i.e., 95%-100% aneurysm embolization).	12 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete occlusion rate of aneurysm at 12-month post-procedure.	The "complete occlusion rate of aneurysm" was defined as the percentage of subjects with the degree of aneurysm embolization scored as Raymond I (i.e., 100% aneurysm embolization).	12 month
Recurrence rate of aneurysm at 12-month post-procedure.	The "recurrence rate of aneurysm" was defined as the percentage of subjects with a decrease in the degree of aneurysm embolization at the follow-up visit as compared with immediately post-procedure.	12 month
Retreatment rate of aneurysm at 12-month post-procedure.	The "retreatment of aneurysm" was defined as the percentage of subject who received retreatment for the recurrence of target aneurysms during the follow-up period	12 month
Device-related serious adverse events at 1, 6, and 12 months after surgery;		12 month
The incidence of ipsilateral stroke or neurologic death of the target aneurysm within 12 months.		12 month
The incidence of ipsilateral ischemic stroke of the target aneurysm within 12 months.		12 month

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Successful occlusion rate of aneurysm at 18-month post-procedure.	It was defined as the percentage of subjects with the degree of aneurysm embolization scored as Raymond I or II (i.e., 95%-100% aneurysm embolization).	18 month
Recurrence rate of aneurysm at 18-month post-procedure.	The "recurrence rate of aneurysm" was defined as the percentage of subjects with a decrease in the degree of aneurysm embolization at the follow-up visit as compared with immediately post-procedure.	18 month
Retreatment rate of aneurysm at 18-month post-procedure.	The "retreatment of aneurysm" was defined as the percentage of subject who received retreatment for the recurrence of target aneurysms during the follow-up period	18 month
The incidence of ipsilateral stroke or neurologic death of the target aneurysm within 18 months.		18 month
Device-related serious adverse events at 18 months after surgery		18 month

Collaborators and Investigators

• Sponsor: MicroPort NeuroTech Co., Ltd.
• Investigators: Principal Investigator: Jianmin Liu, Changhai Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 24, 2023
• Primary Completion (Estimated): October 31, 2025
• Study Completion (Estimated): June 1, 2026

Study Registration Dates

• First Submitted: March 4, 2024
• First Submitted That Met QC Criteria: June 13, 2024
• First Posted (Actual): June 20, 2024

Study Record Updates

• Last Update Posted (Actual): June 20, 2024
• Last Update Submitted That Met QC Criteria: June 13, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Intracranial Arterial Diseases; Aneurysm; Intracranial Aneurysm
• Other Study ID Numbers: SSTH-2023-02-0A

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No